Lees Jennifer S, Fu Edouard L, Faucon Anne-Laure, Elyan Benjamin Mp, Inker Lesley A, Levey Andrew S, Jones Robert J, Wilson Richard H, Mark Patrick B, Carrero Juan-Jesus
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.
NHS Greater Glasgow and Clyde, Glasgow, United Kingdom.
Br J Cancer. 2025 Sep 19. doi: 10.1038/s41416-025-03190-3.
Glomerular filtration rate (GFR) estimation is a key issue in determining cancer treatment eligibility and dosing of treatments with narrow therapeutic index. Yet, little is known about the accuracy of GFR estimation among people with cancer in routine care.
In a cross-sectional study including 1611 adults with cancer referred for 1837 determinations of measured GFR (mGFR), we assessed the accuracy of estimated GFR based on creatinine (eGFRcr), cystatin C (eGFRcys) and their combination (eGFRcr-cys). Accuracy was reported as percentage of patients with estimated values within 30% of mGFR; bias and precision as the median and interquartile range of eGFR-mGFR, respectively. Dosing accuracy was assessed by calculating expected dose of carboplatin for area under the curve of 5 mg/mL/min using the Calvert formula.
Median age was 68 (IQI 61 to 74) years, 38.5% were female with mean mGFR 75 (SD 30) mL/min; 17% had metastatic disease. Accuracy, bias and precision were best for eGFRcr-cys. Using eGFRcr would recommend an "overdose" of carboplatin in 10-20% of participants: this was 3-4 times less common using eGFRcr-cys.
eGFRcr-cys equations provide the most accurate estimates of mGFR in patients with cancer, with potential to improve dosing accuracy substantially compared to eGFRcr.
肾小球滤过率(GFR)估计是确定癌症治疗资格和窄治疗指数治疗剂量的关键问题。然而,在常规护理中,癌症患者中GFR估计的准确性鲜为人知。
在一项横断面研究中,纳入了1611名因1837次测定测量GFR(mGFR)而转诊的成年癌症患者,我们评估了基于肌酐的估计GFR(eGFRcr)、胱抑素C(eGFRcys)及其组合(eGFRcr-cys)的准确性。准确性以估计值在mGFR的30%以内的患者百分比表示;偏差和精密度分别以eGFR-mGFR的中位数和四分位数间距表示。使用卡尔弗特公式计算曲线下面积为5mg/mL/min时卡铂的预期剂量,评估给药准确性。
中位年龄为68(四分位间距61至74)岁,38.5%为女性,平均mGFR为75(标准差30)mL/min;17%患有转移性疾病。eGFRcr-cys的准确性、偏差和精密度最佳。使用eGFRcr会建议在10%-20%的参与者中“过量”使用卡铂:使用eGFRcr-cys时这种情况的发生率要低3-4倍。
eGFRcr-cys方程能最准确地估计癌症患者中的mGFR,与eGFRcr相比,有潜力显著提高给药准确性。